Akero Therapeutics stock crashed 65% on Tuesday: what happened?
Akero Therapeutics Inc (NASDAQ: AKRO) crashed more than 65% this morning after reporting interim results of SYMMETRY – a Phase 2b study of its non-alcoholic steatohepatitis (NASH) candidate. Akero Therapeutics’ EFX failed a key test On Tuesday, the biotech firm said its Efruxifermin did not perform significantly better than placebo in the said clinical trial. […]